Phase 2 Refractory Multiple Myeloma Clinical Trials
40 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 40 trials
Recruiting
Phase 2
18F-Fluciclovine PET/CT in Multiple Myeloma
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 2
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG)40 enrolled5 locationsNCT06421675
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1Phase 2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals150 enrolled2 locationsNCT07455851
Recruiting
Phase 2
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Relapsed Refractory Multiple Myeloma (RRMM)Extramedullary Disease in Multiple MyelomaPMD+4 more
M.D. Anderson Cancer Center34 enrolled1 locationNCT07382739
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 2
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia (PCL)
The First Hospital of Jilin University25 enrolled1 locationNCT07509086
Recruiting
Phase 1Phase 2
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07181941
Recruiting
Phase 1Phase 2
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Alliance for Clinical Trials in Oncology88 enrolled40 locationsNCT06232044
Recruiting
Phase 1Phase 2
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)54 enrolled1 locationNCT06876142
Recruiting
Phase 2
Elranatamab in R/R Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Massachusetts General Hospital32 enrolled3 locationsNCT06138275
Recruiting
Phase 2
ELISA in Relapsed/Refractory MM
Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital30 enrolled3 locationsNCT06832865
Recruiting
Phase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.100 enrolled3 locationsNCT07284758
Recruiting
Phase 2
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Benjamin T Diamond, MD30 enrolled1 locationNCT05896228
Recruiting
Phase 2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
University of Miami33 enrolled3 locationsNCT05530421
Recruiting
Phase 2
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic44 enrolled1 locationNCT06940297
Recruiting
Phase 2
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic62 enrolled1 locationNCT05847569